| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Dasatinib | FIMM | pan-cancer | AAC | -0.059 | 0.7 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | manumycin A | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
| mRNA | BRD-K41597374 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.7 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.7 |